Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 2 Patient characteristics by study

From: The prognostic value of nestin expression in newly diagnosed glioblastoma: Report from the Radiation Therapy Oncology Group

Characteristics

7401

(n = 38)

7918

(n = 9)

8302

(n = 30)

8409

(n = 1)

9006

(n = 32)

9305

(n = 3)

9602

(n = 13)

9806

(n = 27)

Total

(N = 153)

Gender

         

   Male

27 (71%)

4 (44%)

22 (73%)

1 (100%)

20 (63%)

1 (33%)

5 (38%)

18 (67%)

98 (64%)

   Female

11 (29%)

5 (56%)

8 (27%)

0

12 (38%)

2 (67%)

8 (62%)

9 (33%)

55 (36%)

Race

         

   White

35 (92%)

8 (89%)

28 (93%)

1 (100%)

30 (94%)

3 (100%)

13(100%)

26 (96%)

144 (94%)

   Hispanic

2 (5%)

0

0

0

0

0

0

1 (4%)

3 (2%)

   Black

1 (3%)

1 (11%)

1 (3%)

0

2 (6%)

0

0

0

5 (3%)

   Other

0

0

1 (3%)

0

0

0

0

0

1 (1%)

Neuro. Function (Symptoms)

         

   None/Minor

16 (42%)

3 (33%)

13 (43%)

0

23 (72%)

0

7 (54%)

19 (70%)

84 (54%)

   Moderate

13 (34%)

5 (56%)

16 (53%)

1 (100%)

9 (28%)

3 (100%)

6 (46%)

8 (30%)

59 (38%)

   Major/Severe

8 (21%)

1 (11%)

1 (3%)

0

0

0

0

0

11 (7%)

   Missing

1 (3%)

0

0

0

0

0

0

0

1 (1%)

KPS

         

   ≤ 60

11 (29%)

1 (11%)

2 (7%)

0

1 (3%)

0

0

2 (7%)

17 (11%)

   70–80

13 (34%)

6 (67%)

19 (63%)

1 (100%)

12 (38%)

0

6 (46%)

10 (37%)

67 (44%)

   90–100

14 (37%)

2 (22%)

9 (30%)

0

19 (59%)

3 (100%)

7 (54%)

15 (56%)

69 (45%)

Prior Surgery

         

   Biopsy

5 (13%)

0

1 (3%)

0

1 (3%)

0

0

3 (11%)

10 (7%)

   Part. Resect.

21 (55%)

5 (56%)

22 (73%)

1 (100%)

15 (47%)

1 (33%)

10 (77%)

15 (56%)

90 (59%)

   Tot. Resect.

11 (29%)

4 (44%)

7 (23%)

0

16 (50%)

2 (67%)

3 (23%)

8 (30%)

51 (33%)

   Unknown

1 (3%)

0

0

0

0

0

0

1 (4%)

2 (1%)

RPA

         

   III

6 (16%)

1 (11%)

3 (10%)

0

7 (22%)

2 (67%)

4 (31%)

6 (22%)

29 (19%)

   IV

15 (39%)

3 (33%)

13 (43%)

1 (100%)

16 (50%)

1 (33%)

3 (23%)

11 (41%)

63 (41%)

   V

17 (45%)

5 (56%)

14 (47%)

0

9 (28%)

0

6 (46%)

10 (37%)

61 (40%)